Ann: Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer, page-70

The table below reflects period 2019 - 2022 calendar years for Sanofi's Jevtana (cabazitaxel)

Since then the figures for Q1 and Q2 2023 have been published

Europe sales for half year 2023 is 8 million Euro. If we extrapolate this to estimated full year 2023 it is 16 million Euro

As can be seen in the table below, from a high of 187 million Euro in 2020 to an estimated 16 million this year is a decrease in estimated sales of 171 million Euro (AU$286 million) over this period. Percentage wise it is a 93% loss in Jevtana revenue in Europe over this period

Sanofi are losing a lot of money to generics in Jevtana sales

It makes complete sense to me for Sanofi to be the licensee for Dep Cabazitaxel





Note
Generic competition in Europe began in March 2021 and can be reflected in the Jevtana revenues since then

	Column 1	Column 2	Column 3	Column 4	Column 5
1	year	row	usa	world	europe
2	2022	83<4.4%>	275<3.2%>	391<20%>	33<70.5%>
3	2021	90<5.8%>	253+6.5%	455<12.3%>	112<40.6%)
4	2020	103+2.9%	246+17.9%	536+12.2%	187+10.6%
5	2019	78+17.7%	212+12.3%	458+11%	168+7%